{"id":"thymoglobulin-atg","safety":{"commonSideEffects":[{"rate":"61","effect":"Fever"},{"rate":"48","effect":"Chills"},{"rate":"48","effect":"Leukopenia"},{"rate":"52","effect":"Thrombocytopenia"},{"rate":"48","effect":"Infection"},{"rate":"24","effect":"Rash"},{"rate":null,"effect":"Serum sickness"},{"rate":null,"effect":"Cytokine release syndrome"}]},"_chembl":{"chemblId":"CHEMBL4482864","moleculeType":"Small molecule","molecularWeight":"494.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Thymoglobulin is derived from immunizing rabbits with human thymus lymphocytes, producing antibodies against a broad range of T-cell surface antigens including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, and HLA-DR. Upon administration, these antibodies bind to circulating and tissue-resident T cells, leading to complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and opsonization-mediated clearance. This results in profound T-cell depletion, suppressing the cellular immune response.","oneSentence":"Thymoglobulin is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to multiple T-cell antigens and triggering their destruction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:25.450Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute rejection in renal transplant recipients"},{"name":"Aplastic anemia (severe)"},{"name":"Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT07412470","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-03-13","conditions":"Kidney Transplant Rejection","enrollment":526},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT07269041","phase":"PHASE1, PHASE2","title":"Immune Tolerance Induction After Liver Transplantation","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-02-20","conditions":"Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects","enrollment":12},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT03980769","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-05","conditions":"Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","enrollment":40},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03249831","phase":"PHASE1","title":"A Blood Stem Cell Transplant for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-01-04","conditions":"Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies","enrollment":3},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT07440654","phase":"NA","title":"Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-03-01","conditions":"aGVHD Prophylaxis","enrollment":40},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT07284641","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2026-03-01","conditions":"Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation","enrollment":25},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07216391","phase":"PHASE2","title":"Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-15","conditions":"Type 1 Diabetes Mellitus","enrollment":60},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT02203396","phase":"PHASE2","title":"A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2014-08","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT00882895","phase":"PHASE2","title":"Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2009-05-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":18},{"nctId":"NCT05917405","phase":"PHASE2","title":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-09-14","conditions":"Acute Myeloid Leukemia in Remission","enrollment":302},{"nctId":"NCT03121001","phase":"PHASE2","title":"Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-03-20","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04328727","phase":"PHASE2","title":"Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-04","conditions":"Severe Aplastic Anemia (SAA)","enrollment":36},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT04395222","phase":"PHASE2","title":"Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-07","conditions":"Hematologic Malignancy, Bone Marrow Transplant","enrollment":21},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT07052370","phase":"PHASE1","title":"TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-09-25","conditions":"Hematologic Malignancy","enrollment":30},{"nctId":"NCT07297550","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-15","conditions":"Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia","enrollment":42},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT04083183","phase":"PHASE1, PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":"Non-Malignant Neoplasm","enrollment":40},{"nctId":"NCT00692939","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplantation for Crohn's Disease","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2012-06-26","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT03707262","phase":"PHASE1, PHASE2","title":"Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor","status":"RECRUITING","sponsor":"Jeffrey Veale, MD","startDate":"2019-11-06","conditions":"Renal Transplant Rejection, Tolerance, Kidney Transplant","enrollment":15},{"nctId":"NCT06455319","phase":"PHASE2","title":"Precision Administration of Anti-thymocyte Globulin With or Without Verapamil","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-11-12","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT02143830","phase":"PHASE2","title":"HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-04","conditions":"Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS)","enrollment":70},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT03219359","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Crohn's Disease","status":"RECRUITING","sponsor":"Aaron Etra","startDate":"2018-02-22","conditions":"Crohn Disease","enrollment":50},{"nctId":"NCT02828592","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2016-09-09","conditions":"Severe Aplastic Anemia","enrollment":20},{"nctId":"NCT03630211","phase":"PHASE2","title":"Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-07-31","conditions":"Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease","enrollment":8},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT01624805","phase":"PHASE2","title":"Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-25","conditions":"Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":140},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT04291703","phase":"PHASE2","title":"STOP-T1D Low-Dose (ATG)","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-11-01","conditions":"Diabetes Mellitus, Type 1","enrollment":2},{"nctId":"NCT02512497","phase":"PHASE1","title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2017-12-08","conditions":"Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia","enrollment":23},{"nctId":"NCT04872595","phase":"PHASE2","title":"A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-30","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)","enrollment":59},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT03531736","phase":"PHASE1","title":"T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-09","conditions":"Myeloid Diseases","enrollment":17},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT04558736","phase":"PHASE2","title":"Haploidentical HCT for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-01-21","conditions":"Aplastic Anemia, Bone Marrow Failure Syndrome","enrollment":21},{"nctId":"NCT03597594","phase":"PHASE1, PHASE2","title":"Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-09-02","conditions":"Severe Combined Immunodeficiency","enrollment":4},{"nctId":"NCT04530487","phase":"PHASE2","title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-19","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor","enrollment":1},{"nctId":"NCT03477500","phase":"PHASE3","title":"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2018-03-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT06108739","phase":"PHASE3","title":"ATG Plus Low-dose PT-Cy for GVHD Prevention","status":"TERMINATED","sponsor":"Peking University People's Hospital","startDate":"2023-11-01","conditions":"Hematologic Malignancy","enrollment":66},{"nctId":"NCT02928991","phase":"EARLY_PHASE1","title":"Fludarabine Based RIC for Bone Marrow Failure Syndromes","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2015-04","conditions":"Bone Marrow Failure Syndromes","enrollment":25},{"nctId":"NCT06869265","phase":"PHASE2","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-01","conditions":"Acute Myeloid Leukemia (AML), High Risk Acute Myeloid Leukemia(AML), Relapsed/Refractory Acute Myeloid Leukemia (AML)","enrollment":56},{"nctId":"NCT02845596","phase":"NA","title":"Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Michael Pulsipher","startDate":"2016-08","conditions":"Severe Aplastic Anemia","enrollment":40},{"nctId":"NCT04202835","phase":"PHASE2","title":"ATG Plus PTCy vs ATG for CGVHD Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"McMaster University","startDate":"2020-10-14","conditions":"Acute Leukemia, Myelodysplasia, Chronic Graft-versus-host-disease","enrollment":80},{"nctId":"NCT02162420","phase":"NA","title":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-01-10","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":61},{"nctId":"NCT05996393","phase":"PHASE4","title":"CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2023-09-15","conditions":"Aplastic Anemia","enrollment":86},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT03615105","phase":"PHASE2","title":"Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-25","conditions":"Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)","enrollment":9},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT01758328","phase":"PHASE1","title":"Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT01701986","phase":"PHASE1, PHASE2","title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-25","conditions":"Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":64},{"nctId":"NCT01265537","phase":"NA","title":"A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-06-24","conditions":"Acute Graft Rejection, Diabetes","enrollment":30},{"nctId":"NCT02274662","phase":"PHASE4","title":"Expanded Access Protocol Thymus Transplantation","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2014-08","conditions":"Poor Thymic Function, Immunodeficiency, Athymia","enrollment":11},{"nctId":"NCT01413100","phase":"PHASE2","title":"Scleroderma Treatment With Autologous Transplant (STAT) Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-09-15","conditions":"Systemic Scleroderma","enrollment":21},{"nctId":"NCT05153226","phase":"PHASE3","title":"GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG","status":"ACTIVE_NOT_RECRUITING","sponsor":"DKMS gemeinnützige GmbH","startDate":"2022-03-02","conditions":"Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML","enrollment":640},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT02165007","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2015-01","conditions":"Sickle Cell-thalassemia Disease, Thalassemia","enrollment":7},{"nctId":"NCT06572462","phase":"PHASE2","title":"ATG Individualized Dosing Model in URD-PBSCT.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2020-12-31","conditions":"Cytomegalovirus Infections, Infection Reactivation, Stem Cell Transplant Complications","enrollment":30},{"nctId":"NCT06512545","phase":"NA","title":"Modified Second Haplo-transplantation for Graft Failure","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07-01","conditions":"Graft Failure, Stem Cell Transplant Complications","enrollment":12},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT04521946","phase":"PHASE1","title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-14","conditions":"Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor","enrollment":""},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT05743400","phase":"PHASE4","title":"Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-09-25","conditions":"Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy","enrollment":35},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT04302805","phase":"PHASE3","title":"rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2020-07-27","conditions":"Kidney Transplantation","enrollment":17},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT01664910","phase":"PHASE1, PHASE2","title":"CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-29","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":27},{"nctId":"NCT03367546","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-07-02","conditions":"Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders","enrollment":5},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT05832515","phase":"PHASE1","title":"AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-10-01","conditions":"Multiple Sclerosis","enrollment":200},{"nctId":"NCT03412409","phase":"PHASE2","title":"RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT06238245","phase":"PHASE2","title":"Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-02-28","conditions":"Graft-versus-host Disease, Hematological Malignancies","enrollment":22},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Thymoglobulin","Antithymocyte Globulin","Anti-thymocyte globulin","Antithymocyte globulin","Thymoglobulin, Genzyme"],"phase":"marketed","status":"active","brandName":"Thymoglobulin (ATG)","genericName":"Thymoglobulin (ATG)","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thymoglobulin (ATG) is a small molecule used to treat various blood-related conditions, including Aplastic Anemia, Immunosuppression, Thrombocytopenia, Pancytopenia, and Neutropenia. It is administered as part of conditioning regimens, often in combination with other medications such as Cyclophosphamide and Fludarabine, to prepare patients for unrelated donor transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}